Back to Search
JOHN KREGE, M.D.
M.D.
Endocrinology, Diabetes & Metabolism Physician
NPI: 1538524491Individual
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
01058684A(IN)
Research & Publications (20)
A simple method for determining the probability a new vertebral fracture is present in postmenopausal women with osteoporosis.
PMID 16328604·Osteoporos Int·2006
8-other
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.
PMID 19250060·Curr Med Res Opin·2009
4-observational
Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.
PMID 19351734·J Clin Endocrinol Metab·2009
3-trial
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk.
PMID 19016585·J Bone Miner Res·2009
8-other
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
PMID 18923884·Osteoporos Int·2009
2-rct
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
PMID 19584192·J Clin Endocrinol Metab·2009
4-observational
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
PMID 18283386·Osteoporos Int·2008
4-observational
Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency.
PMID 17911178·J Clin Endocrinol Metab·2007
4-observational
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.
PMID 17609307·J Clin Endocrinol Metab·2007
4-observational
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
PMID 17013567·Osteoporos Int·2007
2-rct
Enhanced prediction of fracture risk combining vertebral fracture status and BMD.
PMID 17245546·Osteoporos Int·2007
8-other
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.
PMID 16896507·Osteoporos Int·2006
1-meta
Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node.
PMID 17082654·J Immunol·2006
7-preclinical
Comments on Initial experience with teriparatide in the United States.
PMID 17022851·Curr Med Res Opin·2006
8-other
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
PMID 17002571·J Bone Miner Res·2006
2-rct
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
PMID 16696744·J Am Geriatr Soc·2006
4-observational
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
PMID 16393431·Curr Med Res Opin·2006
1-meta
Reduced risk of back pain following teriparatide treatment: a meta-analysis.
PMID 16142502·Osteoporos Int·2006
1-meta
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
PMID 16234962·J Bone Miner Res·2005
2-rct
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12443 PEBBLEPOINTE PASS
CARMEL, IN 46033 - Phone
- (317) 640-0211
Quick Facts
- NPI
- 1538524491
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile